<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>To evaluate the biochemical and molecular mechanisms leading to <z:hpo ids='HP_0000096'>glomerulosclerosis</z:hpo> and the variable development of <z:hpo ids='HP_0002621'>atherosclerosis</z:hpo> in patients with familial lecithin cholesterol acyl transferase (LCAT) deficiency, we generated LCAT knockout (KO) mice and cross-bred them with <z:chebi fb="0" ids="39015">apolipoprotein</z:chebi> (apo) E KO, <z:chebi fb="2" ids="39026">low density lipoprotein</z:chebi> receptor (LDLr) KO, and cholesteryl <z:chebi fb="21" ids="35701">ester</z:chebi> transfer protein transgenic mice </plain></SENT>
<SENT sid="1" pm="."><plain>LCAT-KO mice had normochromic <z:hpo ids='HP_0001897'>normocytic anemia</z:hpo> with increased reticulocyte and target cell counts as well as decreased red blood cell osmotic fragility </plain></SENT>
<SENT sid="2" pm="."><plain>A subset of LCAT-KO mice accumulated <z:chebi fb="1" ids="6495">lipoprotein</z:chebi> X and developed <z:hpo ids='HP_0000093'>proteinuria</z:hpo> and <z:hpo ids='HP_0000096'>glomerulosclerosis</z:hpo> characterized by mesangial cell proliferation, <z:mp ids='MP_0000612'>sclerosis</z:mp>, <z:chebi fb="23" ids="18059">lipid</z:chebi> accumulation, and deposition of electron dense material throughout the glomeruli </plain></SENT>
<SENT sid="3" pm="."><plain><z:e sem="disease" ids="C0268239" disease_type="Disease or Syndrome" abbrv="">LCAT deficiency</z:e> reduced the plasma <z:chebi fb="6" ids="39025">high density lipoprotein</z:chebi> (<z:chebi fb="17" ids="39025">HDL</z:chebi>) cholesterol (-70 to -94%) and non-<z:chebi fb="4" ids="47775">HDL cholesterol</z:chebi> (-48 to -85%) levels in control, apoE-KO, LDLr-KO, and cholesteryl <z:chebi fb="21" ids="35701">ester</z:chebi> transfer protein-Tg mice </plain></SENT>
<SENT sid="4" pm="."><plain>Transcriptome and Western blot analysis demonstrated up-regulation of hepatic LDLr and apoE expression in LCAT-KO mice </plain></SENT>
<SENT sid="5" pm="."><plain>Despite decreased <z:chebi fb="17" ids="39025">HDL</z:chebi>, aortic <z:hpo ids='HP_0002621'>atherosclerosis</z:hpo> was significantly reduced (-35% to -99%) in <z:hpo ids='HP_0000001'>all</z:hpo> mouse models with <z:e sem="disease" ids="C0268239" disease_type="Disease or Syndrome" abbrv="">LCAT deficiency</z:e> </plain></SENT>
<SENT sid="6" pm="."><plain>Our studies indicate (i) that the plasma levels of apoB containing <z:chebi fb="2" ids="6495">lipoproteins</z:chebi> rather than <z:chebi fb="17" ids="39025">HDL</z:chebi> may determine the atherogenic risk of patients with <z:e sem="disease" ids="C0473527" disease_type="Disease or Syndrome" abbrv="">hypoalphalipoproteinemia</z:e> due to <z:e sem="disease" ids="C0268239" disease_type="Disease or Syndrome" abbrv="">LCAT deficiency</z:e> and (ii) a potential etiological role for <z:chebi fb="2" ids="6495">lipoproteins</z:chebi> X in the development of <z:hpo ids='HP_0000096'>glomerulosclerosis</z:hpo> in <z:e sem="disease" ids="C0268239" disease_type="Disease or Syndrome" abbrv="">LCAT deficiency</z:e> </plain></SENT>
<SENT sid="7" pm="."><plain>The availability of LCAT-KO mice characterized by <z:chebi fb="23" ids="18059">lipid</z:chebi>, hematologic, and renal abnormalities similar to familial <z:e sem="disease" ids="C0268239" disease_type="Disease or Syndrome" abbrv="">LCAT deficiency</z:e> patients will permit future evaluation of LCAT gene transfer as a possible treatment for <z:hpo ids='HP_0000096'>glomerulosclerosis</z:hpo> in LCAT-deficient states </plain></SENT>
</text></document>